turalio
daiichi sankyo europe gmbh - pexidartinib - giant cell tumor of tendon sheath; synovitis, pigmented villonodular - agentes antineoplásicos - treatment of tenosynovial giant cell tumour.
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplasias de la mama - agentes antineoplásicos - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.
inderm solucion
daiichi sankyo europe gmbh [de] germany - eritromicina ???????????????? ???.?? 10,00 mg - solución tópica - cada g de solución contiene: eritromicina ???????????????? ???.?? 10,00 mg
luivac comprimidos
daiichi sankyo europe gmbh munich - alemania [de] germany - lisado bacteriano de po lo menos 1 x 10 exp 9 gérmenes de 3,00 mgstaphylococcus aureusstreptococcus mitisstreptococcus pyogenesstreptococcus pneumonieklebsiella pnuemoniaeemophilus influenzadistribuido en manita 40 mg(materia prima luivac 43 mg - comprimidos orales - cada comprimido contiene lisado bacteriano de por lo menos 1 x 10 exp 9 gérmenes de 3,00 mg staphylococcus aureus streptococcus mitis streptococcus pyogenes streptococcus pneumoniae klebsiella pnuemoniae emophilus influenza distribuido en manita 40 mg (materia prima luivac 43 mg)
benicar amlo 40 mg - 10 mg tabletas recubiertas
daiichi sankyo venezuela, s.a. - olmesartan medoxomil-amlodipina - tableta recubierta - 40 mg -10 mg
epigan 300 mg capsulas
daiichi sankyo venezuela, s.a. - india - capsulas - 300 mg
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leucemia, mieloide - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.
elzym aspergillus oryzae (amilasa, celulosa, proteasa) y simeticona 120 mg - 100 mg capsulas
daiichi sankyo venezuela, s.a. - aspergillus oryzae (amilasa, celulosa, proteasa) / simeticona - capsula - 120 mg - 100 mg
sevikar hct 20 mg/5 mg/12,5 mg comprimidos recubiertos con pelicula
daiichi sankyo espana s.a. - olmesartan medoxomilo; amlodipino besilato; hidroclorotiazida - comprimido recubierto con pelÍcula - 20 mg/5 mg/12,5 mg - olmesartan medoxomilo 20 mg; amlodipino besilato 5 mg; hidroclorotiazida 12,5 mg - olmesartán medoxomilo, amlodipino e hidroclorotiazida
sevikar hct 40 mg/10 mg/12,5 mg comprimidos recubiertos con pelicula
daiichi sankyo espana s.a. - olmesartan medoxomilo; amlodipino besilato; hidroclorotiazida - comprimido recubierto con pelÍcula - 40 mg/10 mg/12,5 mg - olmesartan medoxomilo 40 mg; amlodipino besilato 10 mg; hidroclorotiazida 12,5 mg - olmesartán medoxomilo, amlodipino e hidroclorotiazida